Dan Mendelson is an American businessman and healthcare consultant who founded Avalere Health, a Washington, D.C.-based strategic advisory company, after serving in the Clinton White House.[1] His opinions have been cited in The New York Times,[2] The Wall Street Journal,[3] National Public Radio, and Bloomberg, among other news outlets.[4][5] He is the author of numerous papers and several editorials.[6][7][8]
Mendelson is also an Executive in Residence at the Fuqua School of Business at Duke University.[9] In 2021, Mendelson left Avalere to become the founding CEO of Morgan Health, a healthcare-focused subsidiary of JPMorgan Chase.
Early life and education edit
Mendelson was born in Fort Belvoir, Virginia and grew up in Bethesda, Maryland. He earned a B.A. from Oberlin College and a Masters of Public Policy from Harvard University’s John F. Kennedy School of Government.
Career edit
Mendelson began his career in health policy working for Professor William B. Schwartz at Tufts University, and co-authored a range of articles during that time.[10] He next served as senior vice president of The Lewin Group and director of its Medical Technology Practice.
Before founding Avalere, Mendelson served as associate director for health at the White House Office of Management and Budget during the Clinton administration. In this position, he was responsible for preparing the president’s health budget in consultation with other White House offices, managing the appropriations process with members of Congress and their staffs and overseeing a range of management and budget issues in the U.S. Department of Health and Human Services, the United States Department of Veterans Affairs, and the Office of Personnel Management.
On leaving the White House in 2000, Mendelson founded The Health Strategies Consultancy, renamed Avalere Health in 2005. The company provides advisory services, research, and data products to a range of commercial and non-profit customers with interests in healthcare, providing oft-cited studies on Medicare, Medicaid, the 340B Drug Pricing Program, and the health insurance marketplace. Mendelson served as CEO of Avalere until 2015 when he sold the firm to Inovalon Holdings to focus the efforts of the group on deployment of platforms to improve quality.[11] He continues to serve as an advisor to Avalere.
Board memberships edit
Mendelson serves on the board of directors of Champions Oncology. He previously served on the boards of Coventry Health Care, PharMerica, HMS Holdings, and Audacious Inquiry.
References edit
- ^ "Team". avalere.com. Retrieved 2018-05-21.
- ^ "Choice of Health Plans to Vary Sharply From State to State". The New York Times. September 23, 2009.
- ^ "Sticker Shock: Some Medicare Part D Beneficiaries Will Pay More Next Year". The Wall Street Journal. November 19, 2014.
- ^ "Obamacare Facing More Scrutiny From Ascendant Republicans". Bloomberg. November 5, 2014.
- ^ "Sticker Shock: Some Medicare Part D Beneficiaries Will Pay More Next Year". The Wall Street Journal. November 19, 2014.
- ^ Mendelson, DN. (December 1991), The Problem of Rising Health Care Costs., Critical Issues in American Health Care Delivery and Finance Policy.
- ^ Mendelson, DN; Carino, TV (February 2005), "Evidence-Based Medicine in the United States: De Rigueur or Dream Deferred?", Health Affairs, 24 (1), Health Affairs.: 133–136, doi:10.1377/hlthaff.24.1.133, PMID 15647224
- ^ Mendelson, Salinsky, EM (June 1997), "Health Information Systems and the Role of State Government.", Health Affairs, 16 (3), Health Affairs.: 106–19, doi:10.1377/hlthaff.16.3.106, PMID 9141327
{{citation}}: CS1 maint: multiple names: authors list (link) - ^ "Duke Margolis Center Health Policy Launches". Duke. February 9, 2017.
- ^ Schwartz, WB; Mendelson, DN (April 11, 1991), "Hospital Cost Containment in the 1980s: Hard Lessons Learned and Prospects for the 1990s.", New England Journal of Medicine, 324 (15): 1037–1042, doi:10.1056/NEJM199104113241506, PMID 2005941
- ^ "Inovalon to acquire Avalere for $140M". Modern Healthcare. August 24, 2015.